Conference Calendar

March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017

March 14-December 31 - Canaccord Genuity Musculoskeletal Conference

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art

RSS



app icon

iPhone

app store icon

Kindle



Orthopedic and Dental Industry News Complete Archive »

Isto Holdings to Acquire Arteriocyte Medical Systems BY ANDREW VAHRADIAN, OCTOBER 19, 2016

Isto Holdings entered into an agreement to acquire Arteriocyte Medical Systems Inc., a developer of point-of-care technology to assist patients in the healing process after surgery.

Established in 2007, Arteriocyte offers the MAGELLAN Autologous Platelet Separator System, an automated platelet separator device designed to help patients heal faster from cardiac, orthopedic and vascular surgical procedures. MAGELLAN separates the peripheral blood or a combination of peripheral blood and bone marrow of a patient to create Platelet Rich Plasma (PRP) as well as Platelet Poor Plasma (PPP), biologic concentrator materials that are applied to the surgical site to try and make it heal faster. Such materials can be mixed with autograft and/or allograft bone prior to application as well. The company also provides sterile disposables.

Post transaction-close, the companies will integrate themselves under the name "Isto Biologics" and become a pure-play provider focused on solutions for the spine, orthopedics, and functional-medicine markets. Isto's present-day portfolio includes bone-growth and cell-therapy products.

The combined company will be headquartered in St. Louis, MO and maintain Arteriocyte's operations in Hopkinton, MA. George Dunbar, the current CEO of Isto Technologies, will serve as CEO of Isto Biologics.

Email this to a colleague: